Nov 13, 2002
Guidant and Genzyme Announce Cross-License Agreement

Deal Demonstrates Guidant's Commitment to Innovation and Intellectual Property

Indianapolis, Ind. and Cambridge, Mass. - Guidant Corporation (NYSE and PCX: GDT), a world leader in the treatment of cardiac and vascular disease, and Genzyme Biosurgery (Nasdaq: GZBX), a division of Genzyme Corp., today announced a cross-license agreement related to certain patents for products used in "off-pump" or beating heart cardiac bypass surgery. Under the agreement, Genzyme will make a one-time license fee payment to Guidant and pay ongoing royalties on the sale of these products. Guidant will also obtain a license to certain Genzyme patents subject to certain provisions in the agreement.

"Guidant''s patent portfolio strength in the area of beating heart surgery comes from a strong commitment to innovation and leadership," said Nicky Spaulding, president, Cardiac Surgery, Guidant. "We are pleased to have acquired access to Genzyme''s portfolio in this area."

"This cross-license agreement with Guidant will further strengthen Genzyme Biosurgery''s work in beating heart surgery," said Duke Collier, president, Genzyme Biosurgery. "Access to Guidant''s intellectual property provides us the opportunity to continue the success of our current off-pump product line, which will help us develop the kinds of new and next-generation products that have made us a leader in this exciting surgical area."

Guidant Corporation pioneers lifesaving technology, giving an opportunity for better life today to millions of cardiac and vascular patients worldwide. The company, driven by a strong entrepreneurial culture of more than 10,000 employees, develops, manufactures and markets a broad array of products and services that enable less invasive care for some of life''s most threatening medical conditions. For more information visit www.guidant.com.

Genzyme Biosurgery is a leading developer of novel biotherapeutic products used to treat serious diseases that are managed primarily by surgeons. Its products and pipeline are concentrated in the rapidly growing markets of orthopedics and heart disease, and in broader surgical applications. Genzyme Biosurgery is a division of Genzyme Corporation.

NOTE TO MEDIA: For more information about Guidant, including its products and services, please visit the company''s newsroom at www.guidant.com/newsroom.